Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib for Recurrent or Progressive Meningioma
NCT05425004Phase 2Recruiting
- Sponsor
- Baptist Health South Florida
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in meningioma, sponsored by Baptist Health South Florida. Primary endpoint: Progression-Free Survival at 6 months. Started Jun 2022; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT05425004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425004.